구강 편평상피세포암 마우스 모델에서 상피성장인자 수용체 억제제를 적용한 분자표적치료
Targeted Molecular Therapy in a Murine Model of Oral Squamous Cell Carcinoma with an Epidermal Growth Factor Receptor Inhibitor
박영욱,
소속 상세정보
박영욱 ( Park Young-Wook ) - 강릉대학교 치과대학 구강악안면외과학교실
KMID : 0360120090310010008
Abstract
Purpose: We determined the therapeutic effect of an epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb), cetuximab (Erbitux) on the growth of oral squamous cell carcinoma (OSCC) xenografted in athymic nude mice.
Experimental Design We induced subcutaneous tumors by inoculating human tumor cell suspension into the right flank of nude mice. Nude mice with subcutaneous tumors were randomized to receive cetuximab alone, paclitaxel alone, cetuximab plus paclitaxel, or a placebo (control). Antitumor mechanisms of cetuximab were determined by immunohistochemical and apoptosis assays.
Results: Cetuximab, paclitaxel, and cetuximab/paclitaxel combined therapy resulted in 50%, 52%, 67% in vivo inhibition of tumor proliferation, respectively. Tumors of mice treated with cetuximab plus paclitaxel demonstrated decreased PCNA-positive tumor cells and increased apoptotic tumor cells, which slowed growth of the murine tumors.
conclusion: These data show that EGFR can be a molecular target for the treatment of OSCC. And combination therapy with cetuximab and paclitaxel warrants further clinical study.
키워드
Oral squamous cell carcinoma;Epidermal growth factor receptor;Cetuximab;Molecular target
원문 및 링크아웃 정보
등재저널 정보